Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anticocaine medications

Producción científica: Review articlerevisión exhaustiva

33 Citas (Scopus)

Resumen

Cocaine is highly addictive and no anticocaine medication is currently available. Accelerating cocaine metabolism, producing biologically inactive metabolites, is recognized as an ideal anticocaine medication strategy, especially for the treatment of acute cocaine toxicity. However, currently known wild-type enzymes have either too low a catalytic efficiency against the abused cocaine, in other words (-)-cocaine, or the in vivo half-life is too short. Novel computational strategies and design approaches have been developed recently to design and discover thermostable or high-activity mutants of enzymes based on detailed structures and catalytic/inactivation mechanisms. The structure- and mechanism-based computational design efforts have led to the discovery of high-activity mutants of butyrylcholinesterase and thermostable mutants of cocaine esterase as promising anticocaine therapeutics. The structure- and mechanism-based computational strategies and design approaches may be used to design high-activity and/or thermostable mutants of many other proteins that have clear therapeutic potentials and to design completely new therapeutic enzymes.

Idioma originalEnglish
Páginas (desde-hasta)515-528
Número de páginas14
PublicaciónFuture Medicinal Chemistry
Volumen1
N.º3
DOI
EstadoPublished - jun 2009

Nota bibliográfica

Funding Information:
The patients and their families are warmly acknowledged for their participation. We greatly thank L. Dauche and E. Eymard-Pierre (both of INSERM U384) and D. Recan (banque de cellules, Hôpital Cochin) for their help in processing blood samples. This work was supported by grants from the European Leukodystrophy Association, INSERM projet PROGRES, the Centre National de la Recherche Scientifique (to D.R., D.P.D., and A.D.), the National Institutes of Health (to M.B. and A.M.), the Jean Pierre and Nancy Boespflug Myopathic Research Foundation, and a fellowship from the Association Française de Recherche en Génétique (to D.R.). We are also indebted for a grant, to study genetic leukodystrophies, from Ricerca Finalizzata Strategica of the Italian Ministry of Health.

Financiación

FinanciadoresNúmero del financiador
National Institute on Drug AbuseR01DA021416

    ASJC Scopus subject areas

    • Molecular Medicine
    • Pharmacology
    • Drug Discovery

    Huella

    Profundice en los temas de investigación de 'Recent progress in protein drug design and discovery with a focus on novel approaches to the development of anticocaine medications'. En conjunto forman una huella única.

    Citar esto